Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may reduce the risk of developing cancer-related lymphedema following axillary lymph node dissection (ALND) Leave a reply - National Lymphedema Network

Highlighting Advances in Lymphedema

View all (98) posts »

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may reduce the risk of developing cancer-related lymphedema following axillary lymph node dissection (ALND) Leave a reply

Posted By Administration, Saturday, June 14, 2025

Link to Article
Publish Date: September 3, 2024
Source: Frontiers in Pharmacology

Tags: 2024. breast cancer lymphedema on September 5

Share |

Permalink | Comments (0)

Filter by this tag »
Show all posts with this tag »
Find everyone who has used this tag »

Latest News more

10/15/2025Updated: NLN Position Paper on Lymphedema Treatment and Diagnosis

Calendar more

10/30/2025
NLN Clinical Focus Group - Start Strong

11/5/2025
NLN Clinical Focus Group - Clinical Practice Barriers

Featured Members

Research Surveys

	Cancer Survivorship and Disability Identity: a study towards increased support for cancer survivors
	Exploring the Educational Needs of Individuals Living with Lymphedema
	Lipedema: Understanding the Whole Picture

Contact Us

National Lymphedema Network
2229 Bridge Avenue #667
Point Pleasant, NJ 08742
(800)-541-3259
nln@lymphnet.org

Patient Support Team

800-541-3259
patientsupport@lymphnet.org

Quick Links

All contents © 2025 National Lymphedema Network. All rights reserved. Use of this and other NLN associated websites and platforms constitutes acceptance of our Terms and Conditions.

Connect with Us

Membership Management Software Powered by YourMembership :: Legal